About Uncharacterized protein C20orf96
Uncharacterized protein C20orf96 (C20orf96) is a protein
from Homo sapiens identified by UniProt accession
Q9NUD7, 363 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | Uncharacterized protein C20orf96 |
|---|
| UniProt accession | Q9NUD7 |
|---|
| Gene | C20orf96 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 363 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (20)
Diseases linked to this target (Open Targets).
- Lynch syndrome · score 0.08
- colorectal cancer, susceptibility to, 3 · score 0.06
- inflammatory bowel disease · score 0.06
- Hirschsprung disease · score 0.06
- Meckel's diverticulum · score 0.06
- familial adenomatous polyposis 2 · score 0.05
- AXIN2-related attenuated familial adenomatous polyposis · score 0.05
- anal canal carcinoma · score 0.05
- hereditary mixed polyposis syndrome · score 0.05
- Lynch syndrome 8 · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NUD7-F1 | alphafold | PREDICTED | 75.99 | — |
Amino-acid sequence (363 residues)
MAHVLQKPKH SGTHSIVQEF QVPDYVPWQQ SKQETKPSTL PPVQQANSLH TSKMKTLTRV QPVFHFKPTT VVTSCQPKNP RELHRRRKLD PGKMHAKIWL MKTSLRSGRA ALRELRSREN FLSKLNRELI ETIQEMENST TLHVRALLQQ QDTLATIIDI LEYSNKKRLQ QLKSELQEWE EKKKCKMSYL EQQAEQLNAK IEKTQEEVNF LSTYMDHEYS IKSVQISTLM RQLQQVKDSQ QDELDDLGEM RRKVLESLSD KIQKKKKKIL SSVVAETQRP YEEALLQKMW ESQDFLKCMQ RFREIIDQFE ENMPVLRAEV EELQAQTREP REVIFEDVLL RRPKCTPDMD VILNIPVEEP LPF
Explore Uncharacterized protein C20orf96 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets